Compare · DXCM vs TCMD
DXCM vs TCMD
Side-by-side comparison of DexCom Inc. (DXCM) and Tactile Systems Technology Inc. (TCMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and TCMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 62.7x TCMD ($527.6M).
- DXCM has hit the wire 6 times in the past 4 weeks while TCMD has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 9 for TCMD).
- Company
- DexCom Inc.
- Tactile Systems Technology Inc.
- Price
- -
- -
- Market cap
- $33.10B
- $527.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2016
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 9
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Tactile Systems Technology Inc.
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; and Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest TCMD
- Amendment: SEC Form SCHEDULE 13G/A filed by Tactile Systems Technology Inc.
- Chief Executive Officer Dodd Sheri Louise sold $323,243 worth of shares (10,978 units at $29.44), decreasing direct ownership by 5% to 232,907 units (SEC Form 4)
- SEC Form 10-Q filed by Tactile Systems Technology Inc.
- Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results
- Tactile Systems Technology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026
- Tactile Systems Technology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients
- Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy
- Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference